PharmaShots | Incisive News in 3 Shots

Subscribe Now

Jasper Therapeutics

Jasper Therapeutics Reports First Patient Dosing with Briquilimab in P-Ib/IIa Trial for Treating Chronic Inducible Urticaria

Jasper Therapeutics Reports First Patient Dosing with Briquilimab in P-Ib/IIa Trial for Treating Chronic Inducible Urticaria

March 20, 2024

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us